Radius Health Inc - Company Profile
Powered by 
All the sales intelligence you need on Radius Health Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Radius Health Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Radius Health Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Radius Health Inc (Radius Health), a subsidiary of Paratek Pharmaceuticals Inc, is a biopharmaceutical company. It is dedicated to improving the lives of patients with osteoporosis and other bone health conditions. Its lead product, Tymlos, is a prescription medication used to treat osteoporosis in postmenopausal women and men at high risk for bone fractures. Tymlos helps reduce fracture risks and increases bone density in patients who have not responded to other treatments. The company also offers Binosto, an effervescent tablet for treating osteoporosis. It has expanded its global presence through partnerships with Teijin, Theramex, Labatec, Pharmbio Korea Inc, and Biosidus to support the registration and commercialization of its products. Radius Health is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
7th Floor, 22 Boston Wharf Road, Massachusetts, 02210
Website
www.radiuspharm.com
Telephone
1 617 5514000
No of Employees
293
Industry
Pharmaceuticals and Healthcare
Radius Health Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tymlos: Osteoporosis | Tymlos |
| Binosto: Osteoporosis | Binosto |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In March, the company merged with Paratek Pharmaceuticals Inc. |
| 2026 | Plans/Strategy | In January, the company announced its plans to sell its 57% stake to B‑FLEXION Life Sciences. |
| 2023 | Contracts/Agreements | In September, the company announced an exclusive licensing agreement to EffRx Pharmaceuticals S.A. for BINOSTO in the US markets. |
Competitor Comparison
| Key Parameters | Radius Health Inc | Eli Lilly and Co | AstraZeneca Plc | Novartis AG | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | United States of America |
| City | Boston | Indianapolis | Cambridge | Basel | Thousand Oaks |
| State/Province | Massachusetts | Indiana | Cambridgeshire | Basel-Stadt | California |
| No. of Employees | 293 | 50,605 | 96,100 | 75,267 | 31,500 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Scott Briggs | President; Chief Executive Officer | Executive Board | - | - |
| Bethany Sensenig | Head - Operations; Chief Financial Officer | Senior Management | - | - |
| Erika Tooman | General Counsel; Senior Vice President | Senior Management | - | - |
| Al Medwar | Senior Vice President - Business and Corporate Development | Senior Management | - | - |
| Renata Sklodowska, M.D. | Senior Vice President - Medical Operations | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer